Showing 1031-1040 of 5404 results for "".
- Leading Melanoma Groups Unveil New Campaign Aimed at Menhttps://practicaldermatology.com/news/20120515-leading_melanoma_groups_unveil_new_campaign_aimed_at_men/2459800/
- National Rosacea Society Awards $25,000 for Research on Rosacea Pathogenesis and Treatmenthttps://practicaldermatology.com/news/national-rosacea-society-awards-25000-for-research-on-rosacea-pathogenesis-and-treatment/2488784/The National Rosacea Society (NRS) has awarded two research grants totaling $25,000 to support investigations into the underlying mechanisms of rosacea, including vascular inflammation, immune system interactions, and the potential association between Helicobacter pylori infection and di
- TOGETHER-PsO Biomarker Analysis Examines Ixekizumab and Tirzepatide in Psoriasis With Obesityhttps://practicaldermatology.com/news/together-pso-biomarker-analysis-examines-ixekizumab-and-tirzepatide-in-psoriasis-with-obesity/2488700/A prespecified exploratory analysis of the phase 3b TOGETHER-PsO trial found broader changes in circulating proteins and blood gene expression among adults receiving concomitant ixekizumab (Taltz; Eli Lilly) and tirzepatide (Zepbound; Eli Lilly) than among those receiving ixekizumab alone, accord
- Tapinarof Improves Pediatric Sleep and Family Sleep Impact in ADORING Trial Analysishttps://practicaldermatology.com/news/tapinarof-improves-pediatric-sleep-and-family-sleep-impact-in-adoring-trial-analysis/2488684/Once-daily tapinarof cream 1% was associated with greater improvements in sleep-related symptoms than vehicle among children with atopic dermatitis (AD), according to a post hoc analysis of the phase 3 ADORING 1 and ADORING 2 trials. Mark Boguniewicz, MD, and colleagues evaluated pooled da
- Difamilast Ointment Shows Week 4 Benefits in Pediatric and Adult Atopic Dermatitis Trialshttps://practicaldermatology.com/news/difamilast-ointment-shows-week-4-benefits-in-pediatric-and-adult-atopic-dermatitis-trials/2488681/Difamilast 1% ointment was associated with higher rates of Investigator’s Global Assessment (IGA) success than vehicle at week 4 in separate phase 3 studies involving adults and children with atopic dermatitis (AD), according to an integrated review presented at the 2026 Fall Clinical Dermatology
- Simone Biles Shares Seborrheic Dermatitis, Eczema Journey in New Arcutis Campaignhttps://practicaldermatology.com/news/simone-biles-shares-seborrheic-dermatitis-eczema-journey-in-new-arcutis-campaign/2488580/Arcutis has partnered with World Champion gymnast Simone Biles to launch Skin to Believe In, an awareness campaign focused on seborrheic dermatitis and atopic dermatitis, according to a press release from the company. The campaign centers on Biles’ experience managin
- Science of Skin Urticaria Discussion Highlights Expanding Treatment Options and Need to Measure Disease Controlhttps://practicaldermatology.com/news/science-of-skin-urticaria-discussion-highlights-expanding-treatment-options-and-need-to-measure-disease-control/2488529/The growing treatment armamentarium for chronic spontaneous urticaria (CSU) is giving dermatologists more opportunities to individualize therapy, but effective management begins with fundamentals: selecting and adequately dosing antihistamines, identifyi
- Zasocitinib Could Raise the Efficacy Bar for Oral Psoriasis Treatment, Takeda Doctor Sayshttps://practicaldermatology.com/news/zasocitinib-could-raise-the-efficacy-bar-for-oral-psoriasis-treatment-takeda-doctor-says/2488520/Following the US Food and Drug Administration's decision to grant Priority Review to zasocitinib (TAK-279) for adults with moderate-to-severe plaque psoriasis, Chinwe Ukomad
- LEO Pharma Closes Dersimelagon Acquisition as FDA Accepts NDAhttps://practicaldermatology.com/news/leo-pharma-closes-dersimelagon-acquisition-as-fda-accepts-nda/2488489/LEO Pharma announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and granted Priority Review for the investigational treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The FDA has se
- Sun Pharma Partners with Christian Siriano for Alopecia Areata Awareness Campaignhttps://practicaldermatology.com/news/sun-pharma-partners-with-christian-siriano-for-alopecia-areata-awareness-campaign/2488473/Sun Pharma announced a partnership with fashion designer Christian Siriano on "Regrowth Restyled," a new awareness campaign focused on confidence, self-expression and hair growth support for adults living with severe alopecia areata. Launched during Alopecia Areata Awareness Month, the cam